Assessment of Medical Service Pricing in China's Healthcare System: Challenges, Constraints, and Policy Recommendations

被引:15
作者
Xiong, Wenying [1 ]
Deng, Yufan [2 ,3 ,4 ,5 ]
Yang, Yili [2 ,3 ,4 ,5 ]
Zhang, Yumeng [2 ,3 ,4 ,5 ]
Pan, Jay [2 ,3 ,4 ,5 ]
机构
[1] Sichuan Prov Healthcare Secur Adm, Chengdu, Peoples R China
[2] Sichuan Univ, West China Sch Publ Hlth, Healthcare Evaluat & Org Anal HEOA Grp, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China
[4] Sichuan Univ, Inst Hlth Cities, Chengdu, Peoples R China
[5] Sichuan Univ, West China Res Ctr Rural Hlth Dev, Chengdu, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
medical service pricing; price setting; price regulation; health reform; China; HOSPITAL COMPETITION; REFORM; PROGRESS;
D O I
10.3389/fpubh.2021.787865
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Medical service pricing reform was considered as one of the focuses of China's remarkable health reform. This paper preliminarily assessed the roles of medical service pricing in the context of China's healthcare system. Specifically, we described the potential roles of medical service pricing in China and pointed out relevant challenges that emerged in practice as the result of reform-related activities. Multiple constraint factors that might have induced undesired outcomes were then recognized, including the excessive diversity and specialization of medical services, the price inelasticity of patients' demand, and the inadequate capability of both medical institutions and administrations. Finally, we provided policy recommendations to inform the ongoing medical service pricing reform in China from a long-term perspective.
引用
收藏
页数:9
相关论文
共 44 条
[1]   China progresses with health reform but challenges remain [J].
Alcorn, Ted ;
Bao, Beibei .
LANCET, 2011, 377 (9777) :1557-1558
[2]  
ARROW KJ, 1963, AM ECON REV, V53, P941
[3]   Institutions for health care price setting and regulation: A comparative review of eight settings [J].
Barber, Sarah L. ;
Lorenzoni, Luca ;
Ong, Paul .
INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 2020, 35 (02) :639-648
[4]  
Barber SL, 2019, WHOWKCOECDK18014, P298
[5]  
Chen X., 2017, STUDY PRICING MEDICA
[6]  
Cheng Y., 2010, REFORM OPENNING, V20, P77, DOI [10.16653/j.cnki.32-1034/f.2010.20.135, DOI 10.16653/J.CNKI.32-1034/F.2010.20.135]
[7]  
China National Bureau of Statistics, 2020, STAT YB CHINA 2020
[8]   A retrospective and prospective assessment of the zero-markup drug reform in China from the perspective of policy diffusion [J].
Deng, Jianwei ;
Tian, Huilin ;
Guo, Yilun ;
Ma, Tengyang ;
Sun, Yangjie ;
Zhang, Shiyang ;
Yang, Tianan ;
Tian, Xu .
INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 2018, 33 (04) :E918-E929
[9]  
Folland S., 1997, EC HLTH HLTH CARE
[10]   Intended and unintended impacts of price changes for drugs and medical services: Evidence from China [J].
Fu, Hongqiao ;
Li, Ling ;
Yip, Winnie .
SOCIAL SCIENCE & MEDICINE, 2018, 211 :114-122